COOKIES USE We use necessary system cookies for the correct functioning of the website and optional Google Analytics cookies to obtain visit statistics. +info
Cookies config
Necessary
The necessary cookies are absolutely essential for the website to work properly. This category only includes cookies that guarantee basic website security and functionality. These cookies do not store any personal information.
Name
Proveedor
Propiedad
Finalidad
Caducidad
+info
_GRECAPTCHA
google.com
Own
provide antispam protection with the reCaptcha service
6 months
cc_cookie_accept
fidmag.org
Own
Usada per confirmar que l'usuari ha confirmat / refusat les cookies (i quins tipus accepta)
1 any
WEB_SESSION
fidmag.org
Own
Cookie técnica: cookie de sessió PHP. Guarda l'id de sessió d'usuari.
al acabar la sessió
Analisys
Analytical cookies are used to understand how visitors interact with the website. These cookies help to provide information on meters, the name of visitors, the percentage of bounces, the font of the traffic, etc.
Name
Proveedor
Propiedad
Finalidad
Caducidad
+info
_ga
Google Analytics
From third parties
Cookie d'anàlisi o mesurament: Identifica els usuaris i proporciona informació sobre com els usuaris troben la pàgina web i com la utilitzen per a realització d'Informes estadístics
2 anys
_gat_gtag_UA_141706552_1
Google Analytics
From third parties
Cookie d'anàlisi o mesurament: Tracking per part de google per google analytics
1 minut
_gid
Google Analytics
From third parties
Cookie d'anàlisi o mesurament: S'usa per limitar el percentatge de sol·licituds
Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease.
Martinez-Horta S, Perez-Perez J, van Duijn E, Fernandez-Bobadilla R, Carceller M, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Ruiz-Idiago J, Sampedro F, Landwehrmeyer GB, , Kulisevsky J
Limited service to collaborators of the network of Sisters Hospitalarias Centers. You will receive a message in your email with a link to download this article.
Abstract
Neuropsychiatric symptoms are common features of Huntington's disease (HD). Whereas most studies have focused on cognitive and neuroimaging markers of disease progression, little is known about the prevalence of neuropsychiatric symptoms in premanifest mutation carriers far-from and close-to disease onset.We obtained neurological, cognitive and behavioral data from 230 participants classified as premanifest far-from (preHD-A) and close-to (preHD-B) motor-based disease onset, early-symptomatic (early-HD), and healthy controls. Frequency and severity of neuropsychiatric symptoms were assessed with the short Problem Behaviors Assessment for HD (PBA-s). The odds-ratio (OR) to present symptoms in the clinical range was calculated using the control group as reference. Logistic regression analysis was used to explore relationships between neuropsychiatric symptoms and medication use.Prevalence of depression was similar in all groups. Apathy was already present in 32% of preHD-A increasing to 62% of early-HD patients. The probability of presenting apathetic symptoms was 15-88 times higher in preHD-A and preHD-B respectively than in healthy controls. Irritability and executive dysfunction were present in both preHD-B and early-HD.Neuropsychiatric symptoms are highly prevalent in HD, already in the premanifest stage, with increasing prevalence of irritability, apathy and executive dysfunction closer to onset. Compared to controls, HD mutation carriers have the highest probability to develop apathy, with an increasing prevalence along disease stages. Our findings confirm the high prevalence of neuropsychiatric symptoms in HD, already many years before the onset of motor symptoms, with apathy as an early manifestation and core neuropsychiatric feature of the disease.